Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32826572.
- Also identified by DOI 10.14309/ajg.0000000000000830 and PMC identifier 7473798.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome. We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD. COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-α agents have been associated with better clinical outcomes. Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-α agents seem to mitigate the course of COVID-19.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Immunosuppressive Agents
- Inflammatory Bowel Diseases
- Pneumonia, Viral
- Tumor Necrosis Factor-alpha